Company

Founders pioneering a breakthrough platform

Our co-founders Dr. Joe Loscalzo and Dr. Albert-Laszlo Barabasi pioneered the building of the map of human biology – the Human Interactome  –  that explains how proteins expressed from genes interact to cause specific disease phenotypes, providing the wiring diagram needed to interpret dynamic molecular data from patients to determine an individual’s unique disease biology.

Science publications

A leadership team with strong focus on culture

  • Alif Saleh
    Alif Saleh
    Chief Executive Officer

    Alif is a pioneer in using network science and AI to solve some of the most difficult challenges in healthcare today. As the CEO of Scipher Medicine, he is pioneering the development of technologies to match individual patients with the most effective therapies. Concerned by the healthcare system’s inability to prescribe the right drugs to the right patients, Alif and the Scipher Medicine team are developing and commercializing precision diagnostics and therapeutics in autoimmune diseases. With a unique global perspective on healthcare, Alif has led cross-disciplinary teams throughout Asia, Europe, and the Americas and raised over $350 million in venture and private equity capital to bring novel technologies to market. Alif was most recently featured on The Bio Report podcast (“Bringing Precision Medicine to Autoimmune Disease”) and at the BIO International Convention (“Precision Medicine Outside Oncology: One Size Does Not Fit All).” Through Alif’s leadership, entrepreneurial spirit, and scientific expertise, Scipher will continue to leverage AI and network medicine to continue improving healthcare utilization and patient outcomes for years to come.

  • Slava Akmaev, PhD
    Slava Akmaev, PhD
    Chief Technology Officer and Head of Therapeutics

    Slava has been named one of the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare and is a frequent speaker at some of the most prolific industry events. Slava is the inventor of several issued and pending patent applications and has published more than 20 peer-reviewed articles in computational biology, artificial intelligence, and molecular biology. Slava’s experience includes developing data-driven technologies for target discovery and precision medicine and launching multiple commercial diagnostic products at Berg and GNS Healthcare. Slava started his career working for Genzyme Genetics where he developed novel statistical approaches for high-throughput “omics” data. Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder.

  • Jerry Conway
    Jerry Conway
    Senior Vice President, Market Access

    Jerry specializes in the successful reimbursement of novel molecular diagnostic platforms, having obtained broad payer coverage with value-based payment from Medicare, employers and commercial payers. He has built an illustrious career of working with key payers to ensure product coverage upon market launch at companies such as Foundation Medicine, Genzyme Genetics and Corning Metpath. Most recently, Jerry was the Executive Vice President at CDx Diagnostics.

  • Brian McEvilly
    Brian McEvilly
    Vice President, Strategic Alliances

    Since joining Scipher Medicine in May 2020, Brian has brought his 20+ years of successful commercialization leadership experience to bear. Top achievements prior to joining include the successful introduction of numerous novel LDTs and culminating 5 years of executive management at Exagen Inc with a successful IPO. Prior to his work at Exagen, Brian delivered significant growth to organizations including Inova Diagnostics, Hologic, Cypress Bioscience, and Quidel. An industry veteran, Brian has received numerous awards including being recognized as the Diagnostics Marketer of The Year by the Medical Marketing Association. In every instance, his professional efforts are dedicated toward improving healthcare through better care, improved patient outcomes, and reduced overall costs. Brian earned a Master of Business Administration from University of California, Irvine, and a Bachelor of Arts in Business from the University of San Diego.

  • Alison Stowell
    Alison Stowell
    Chief People Officer

    Alison joined Scipher Medicine with 20+ years of Human Resources experience. Prior to joining Scipher, she was the Practice Leader at the Dominis Group where she worked with executives of various stage startup companies to scale their organizations.  Her passion is in developing individuals while growing and leading high-performance teams.  Alison has also worked in HR and Talent Acquisition for Akamai Technologies, Allergan and Fidelity Investments.  Alison holds a BA in Political Science from University of Massachusetts, Amherst.

A board of advisors looking to the future

  • Regina Benjamin, MD, MBA
    Regina Benjamin, MD, MBA
    18th Surgeon General of the United States

    Dr. Benjamin served as the 18th U.S. Surgeon General from 2009 to 2013. She was also chair of the National Prevention Council, composed of 17 cabinet-level heads of federal agencies that released the first-ever National Prevention Strategy, whose goal was to change our healthcare system from one based on sickness and disease, to one of wellness and prevention. Dr. Benjamin serves on the boards of Kaiser Foundation Hospitals and Health Plan, Ascension Health, and 3 publicly traded healthcare companies. As a family physician, and Founder of BayouClinic, Inc, Dr. Benjamin is one of the nation’s leading voices on population and preventive health issues.

  • Mariann Byerwalter
    Mariann Byerwalter
    Chairman Emeritus, SRI Intl
    Board of Directors, Pacific Life

    Byerwalter is Chairman Emeritus of the SRI International. She serves on the Stanford Health Care Board of Directors, where she was Chairman of the Board of Directors from 2006 through 2013, and served as the Interim President and CEO of Stanford Health Care in 2016. Byerwalter also sits on the Board of Directors of Pacific Life, Franklin Resources, and Lucile Packard Children’s Hospital. She holds a B.A. degree from Stanford University and an MBA from Harvard Business School.

An amazing team operating in a performance driven culture

View openings now

Our journey

    2001 2003 2013 2015 2016 2017 2018 2019 2020
  1. 2001

    2001

    Human Genome Project completed.

  2. 2003

    2003

    Our founders Drs. Joseph Loscalzo and Laszlo Barabasi begin building the map of human disease biology that explains how proteins expressed from the human genome interact to cause specific diseases.

  3. 2013

    2013

    The map grows to cover 89% of all proteins in human cells, revealing the underlying biological processed causing many of the most common and difficult to treat diseases.

  4. 2015

    2015

    Scipher Medicine is founded.

  5. 2016

    2016

    Research begins to develop predictive drug response tests.

  6. 2017

    2017

    Scipher applies its research to develop a blood test for predicting drug response to anti-TNF therapies, after months of researching and surveying the healthcare system to identify significant clinical and financial pain points.

  7. 2018

    2018

    September: Scipher completes its Series A funding led by Khosla Ventures.
    December: Scipher completes the observational study for its anti-TNF response test in rheumatoid arthritis.

  8. 2019

    2019

    United HealthGroup invests into Scipher.

  9. 2020

    2020

    PrismRA study reads out positive and Scipher launches the test commercially.
    Signs pharma deal with Galapagos to develop targets that are specific to biologically similar sub populations of patients.

Backed by funds and committed individuals disrupting and transforming healthcare and life sciences